title: Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis.
abstract: Nitric oxide (NO) and prostacyclin (PGI2) are two important modulators of renal function under normal conditions; however, little is known on their contributory role in cirrhosis with ascites. In this study, mean arterial pressure, renal hemodynamics, and sodium excretion were measured in 15 rats with cirrhosis and ascites and 16 control rats. Animals were studied in normal conditions, after inhibiting the synthesis of NO (N omega-nitro-L-arginine, 50 micrograms.kg-1.min-1) or prostaglandins (lysin acetylsalicylate, 15 mg.kg-1).min-1 and following the concomitant inhibition of both systems. Cirrhotic rats showed increased systemic pressure sensitivity and blunted renal vasoconstrictor response to nitric oxide inhibition as compared with control rats. As a consequence, the glomerular filtration rate increased in cirrhotic rats but not in control rats. In both groups of animals, NO inhibition was associated with significant increased urinary sodium and fractional sodium excretion. The only significant effect observed after prostaglandin biosynthesis inhibition was a decrease in renal plasma flow in cirrhotic rats. The concomitant inhibition of both systems reduced renal plasma flow and did not change glomerular filtration rate, with no differences between control and cirrhotic rats. Prostaglandin inhibition did not prevent the natriuretic effect of the NO inhibitor in both groups of animals. These results indicate that in experimental cirrhosis both NO and PGI2 play an important role in the maintenance of renal perfusion within normal limits.
authors.affiliation: Hormonal Laboratory, Hospital Clínic i Provincial, University of Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Ros
authors.forename: J
authors.initials: J
authors.lastname: Clària
authors.forename: W
authors.initials: W
authors.lastname: Jiménez
authors.forename: M
authors.initials: M
authors.lastname: Bosch-Marcé
authors.forename: P
authors.initials: P
authors.lastname: Angeli
authors.forename: V
authors.initials: V
authors.lastname: Arroyo
authors.forename: F
authors.initials: F
authors.lastname: Rivera
authors.forename: J
authors.initials: J
authors.lastname: Rodés
mesh_terms: D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D001241:Aspirin / Q000031:analogs & derivatives / Q000494:pharmacology; D011464:Epoprostenol / Q000037:antagonists & inhibitors / Q000502:physiology*; D006439:Hemodynamics / Q000502:physiology; D008106:Liver Cirrhosis, Experimental / Q000503:physiopathology*; D008239:Lysine / Q000031:analogs & derivatives / Q000494:pharmacology; D008297:Male; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000502:physiology*; D019335:Nitroarginine; D051381:Rats; D017208:Rats, Wistar; D012079:Renal Circulation / Q000502:physiology*
chemical_list: D019335:Nitroarginine; D009569:Nitric Oxide; D001120:Arginine; D011464:Epoprostenol; D008239:Lysine; D001241:Aspirin; C010395:acetylsalicylic acid lysinate